RxDoctor Payments Data

Stephanie Coulter, MD

Cardiovascular Disease · Houston, TXNPI 1376566273

Payments from drug & device makers

$26,872in general payments, 2019–2025

Across 740 payments — averaging $36.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$7K
  • Boehringer Ingelheim$4K
  • Abbott$2K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Novartis$1K
  • Johnson & Johnson$1K
  • plus $9K from 41 others

What the payments were for

  • Consulting fees$6,40024%
  • Speaking & faculty fees$5,07019%
  • Travel & lodging$9734%
  • Food & beverage$14,29853%
  • Education$1310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,872 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$383,174
Medicare patients
1,686
Services billed
3,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban302$343,789
JardianceEmpagliflozin210$301,292
EntrestoSacubitril/Valsartan100$136,389
OzempicSemaglutide90$126,194
Repatha SureclickEvolocumab99$102,629
VascepaIcosapent Ethyl64$49,135
XareltoRivaroxaban26$43,243
FarxigaDapagliflozin Propanediol29$32,991
LivaloPitavastatin Calcium26$22,086
Atorvastatin Calcium1,023$13,804
Icosapent Ethyl24$13,593
Metoprolol Succinate566$12,404
BrilintaTicagrelor16$12,166
Pitavastatin Calcium27$11,919
Ezetimibe397$11,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$948$343,789302 claims
Boehringer IngelheimJardiance$4,398$301,292210 claims
NovartisEntresto$1,417$136,389100 claims
Novo NordiskOzempic$1,119$126,19490 claims
AstraZenecaFarxiga, Brilinta$142$45,15745 claims
Johnson & JohnsonXarelto$1,369$43,24326 claims
Kowa Pharmaceuticals America, Inc.Livalo$461$22,08626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →